• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors May Respond To Arteris (AIP) $3.3 Million Defense Funding

    Simply Wall St·10/08/2026 10:28:13
    Listen to the news
    • Arteris announced that its third-party IP security assurance program, developed with BAE Systems and SiFive, received an additional US$3.3 million from the U.S. Trusted and Assured Microelectronics program to refine methods for securing commercially sourced IP in complex SoCs.
    • The expanded collaboration positions Arteris more deeply in mission-critical semiconductor security work, which can influence demand for its IP and integration methodologies as defense and government customers focus on supply chain assurance.
    • We will now examine how Arteris' investment narrative could shift in light of its deeper defense alignment through expanded third-party IP security funding.

    Compare Arteris' defense grade IP focus with other chip designers by scouting the 31 resilient stocks with low risk scores that aim to pair resilient balance sheets with measured risk profiles in semiconductor and security related fields.

    Arteris Investment Narrative Recap

    To own Arteris, you need to buy into a story where complex system on chip designs, AI workloads and chiplet architectures keep pushing customers toward outsourced NoC and security IP, and where that demand eventually supports a path toward smaller operating losses. The latest T&AM funded defense work speaks to relevance in security heavy designs, but does not directly change the near term loss making profile.

    The swing factor still sits in execution on large deals and adoption of newer products like FlexGen and Magillem Packaging, while managing R&D and field engineering spend so costs do not outrun forecast revenue growth. The biggest risk remains customer concentration and the possibility that large chipmakers insource interconnect IP, which would pressure revenue visibility and make the current net loss of US$39.5 million harder to narrow.

    The fresh US$3.3 million extension of the Arteris third party IP security program with BAE Systems and SiFive lines up cleanly with the firm’s hardware security verification portfolio, including Cycuity Radix tools. That connection matters for investors watching whether security focused products can deepen relationships with government and defense aligned customers that typically run long design cycles.

    For the current catalyst mix, this security program reinforces the theme that more complex and regulated chips lean on external IP and tools. This supports the idea of recurring software and IP revenue alongside existing NoC wins like AMD and Whalechip. The operational test is whether these collaborations convert into a broader base of contracts that smooth lumpiness from whale deals and help offset ongoing non GAAP operating losses projected into 2025.

    Arteris' current loss of US$39.5 million is set against analyst assumptions that revenue grows at 24.5% annually and that earnings reach US$18.5 million by 2029. This implies an earnings improvement of about US$58 million over that span.

    Uncover why Arteris' fair value indicates a 75% potential upside to its current price, which could narrow quickly.

    NasdaqGM:AIP 1-Year Stock Price Chart
    NasdaqGM:AIP 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view is that Arteris’ biggest swing factor is not defense security work at all but the pace of AI centric “whale” wins. The most optimistic analysts were already penciling in 31% annual revenue growth and US$28.6 million in earnings by 2029. Those forecasts came before this new government backed security funding, so opinions could shift further.

    Explore 4 other Arteris fair value estimates, including one that suggests up to 120% upside from the current price.

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider forming your own view.

    Looking For More Investment Ideas Beyond Arteris?

    Once you have a view on Arteris, it often helps to cross check that thesis against other opportunities that fit different risk and income profiles.

    • If you want potential growth with tighter risk controls, consider using the 31 resilient stocks with low risk scores that focuses on companies with more resilient business profiles and lower risk scores.
    • For investors searching for value opportunities, review the 29 high quality undervalued stocks that highlights stocks combining stronger cash generation with more conservative balance sheets.
    • If reliable income is a bigger priority for you, scan the 8 dividend fortresses that focuses on higher yielding dividends supported by sturdier fundamentals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.